Navigation Links
InteKrin Therapeutics to Present Phase 2b Clinical Data for Edema at the 2010 American Diabetes Association Annual Meeting
Date:6/18/2010

LOS ALTOS, Calif., June 18 /PRNewswire/ -- InteKrin Therapeutics Inc. announced today it will present 6 month Phase 2b clinical data for edema in diabetic patients showing differentiation for INT131, a Selective PPAR-gamma Modulator (SPPARM), from Actos® pioglitazone, at the American Diabetes Association annual meeting in Orlando, FL, Monday, June 28, 2010 at 2:45 pm EDT during the "Update on BARI 2D --Treatment of Insulin Resistance" session.

Dr. Alex DePaoli, Acting Chief Medical Officer of InteKrin Therapeutics, will present "INT131 Besylate, a Selective PPAR-gamma Modulator (SPPARM), Improved Glycemic Control in Patients with Type 2 Diabetes without Causing the Edema Seen with Pioglitazone."

About INT131

INT131 is a next-generation insulin sensitizer that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of Type 2 Diabetes.  As a selective PPAR-gamma modulator (SPPARM), INT131 has been designed to provide potent glucose lowering and durability of effect without the recognized side effects of the currently available insulin sensitizers which, unlike INT131, are full PPAR-gamma agonists. InteKrin has completed an End-Of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for INT131 and is moving the program into Phase 3 development.

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin has assembled an experienced team of veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.

To learn more about InteKrin, visit www.InteKrin.com.


'/>"/>
SOURCE InteKrin Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
2. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
3. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
4. InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
5. InteKrin Therapeutics Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... 2016 Automation is one of ... to the growing demands for productivity in speed, accuracy, ... systems are already adept of a wide range of ... manual labor. Instrumentation continues to evolve, and is poised ... a few years ago. Originally used mostly by the ...
(Date:4/28/2016)... , April 28, 2016 ... George Phillips und Stephen ...    ArisGlobal®, ein führender Anbieter ... gab heute bekannt, dass neue Führungskräfte zum ... gestoßen sind, die vielfältige Erfahrungen mitbringen.  Dies ...
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... development of oral drug delivery systems, announced today that the ... by Joseph Gunnar & Co. LLC, taking place ... . Nadav Kidron , CEO of Oramed, will present ... Details:   PIONEERS 2016, presented by Joseph ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 29, 2016 , ... Coalition Duchenne, a Newport Beach, California ... Duchenne research, participated in the April 25 U.S. Food and Drug Administration advisory ... The meeting at the Marriott Conference Center in Hyattsville, Maryland was attended by ...
(Date:4/29/2016)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... is time to set the record straight. Traditionally, BC and AD has been referred ... true and offers explanation. , “To start with, the Name of the Savior has ...
(Date:4/28/2016)... St. Petersburg, FL (PRWEB) , ... April 29, 2016 , ... Sublime Beauty® is offering ... of the same product) for 50% off. The discount is applied to the product with ... box is given to those who purchase $250 or more in products. , "So many ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... accessories, is proud to partner with AquaShieldUSA, the country's oldest waterproof cast ... clinic and medical supply stores, the largest selection of daily, night, weatherproof and ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... Cosmetic Town, ... website, cosmetictown.com . The forum section was recently revamped and upgraded to allow ... surgical techniques in use across the country. , According to the senior editor of ...
Breaking Medicine News(10 mins):